With our partner Salesforce, unify sales, marketing and customer service. Accelerate your growth!
RESILIENCE has formalized the acquisition of GIMLI, another French startup founded in 2022 by ALEXANDRE YAZIGI, surgical oncologist, and ANTHONY DUBOIS, expert in clinical data. Specializing in artificial intelligence and the structuring of medical data in oncology, Gimli has developed innovative technology that transforms raw medical reports into standardized and usable data. This operation strengthens Resilience’s approach, which integrates data at the heart of its strategy to personalize care and accelerate therapeutic innovation.
Gimli’s technology is based on natural language processing (NLP) and machine learning to analyze and structure medical data from unformatted records, such as biological reports or clinical notes. This information, which complies with international medical standards, is then hosted directly on the servers of health establishments, guaranteeing its security while allowing its local use. Thanks to this acquisition, Resilience intends to deploy this technology in establishments where it is already implemented, to optimize personalized monitoring and clinical research projects.
We were unable to confirm your registration.
Your registration is confirmed.
Currently, Resilience supports more than 14,000 patients across 100 healthcare establishments. Its remote monitoring platform, associated with a mobile application, already allows remote monitoring and personalized alerts to improve patient care. With the integration of Gimli technologies, this personalization will be further strengthened. Structured data will not only allow a more detailed analysis of patient needs, but also an optimization of care processes, such as the validation of treatment plans or the precise reporting of biological results to doctors.
This acquisition is not limited to improving individual care. It also aims to transform clinical research. By making data easily actionable, Gimli facilitates the creation of cohorts, the selection of patients for clinical trials and the automation of electronic case report forms (eCRFs). These advances reduce the administrative burden on clinicians and increase the accuracy of the data collected, thus accelerating studies and the development of new treatments.
For patients, this means access to care even more adapted to their specific needs. For healthcare professionals, this represents a powerful tool to optimize monitoring and therapeutic decisions. Finally, for researchers, it is a major advance in the use of data to advance the understanding of pathologies and develop innovative treatments.
Jonathan Benhamouco-founder and CEO of Resilience, concludes: “Acquiring Gimli strengthens our ability to personalize care pathways while accelerating clinical research projects. This integration positions us as a leader in therapeutic innovation in oncology. »
